Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Biogen's Sloan Ratio for the quarter that ended in Mar. 2024 was 10.30%.
As of Mar. 2024, Biogen has a Sloan Ratio of 10.30%, indicating there is a warning stage of accrual build up.
Biogen Sloan Ratio % Historical Data
The historical data trend for Biogen's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Biogen's Sloan Ratio % falls into.
Biogen Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Biogen's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Biogen's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 591.6 (Jun. 2023 ) + -68.1 (Sep. 2023 ) + 249.7 (Dec. 2023 ) + 393.4 (Mar. 2024 ) = $1,167 Mil.
Biogen's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 487 (Jun. 2023 ) + 592.4 (Sep. 2023 ) + 12.5 (Dec. 2023 ) + 553.2 (Mar. 2024 ) = $1,645 Mil.
Biogen's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -753.5 (Jun. 2023 ) + -1742.2 (Sep. 2023 ) + -652.3 (Dec. 2023 ) + -66 (Mar. 2024 ) = $-3,214 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (NAS:BIIB) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Biogen has a Sloan Ratio of 10.30%, indicating there is a warning stage of accrual build up.
Biogen Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Biogen's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIIB has been successfully added to your 